Individuals with a history of certain medical conditions, like active cancer, should avoid Tesamorelin therapy.

The duration of therapy varies depending on individual response and healthcare provider like the expert team at Yutopia would help in assessing the duration needed.

Tesamorelin does not interfere with antiretroviral therapy and can be used alongside it.

Coverage varies depending on the insurance provider and policy. Check with your insurance provider for details.

Tesamorelin therapy primarily reduces excess abdominal fat, leading to improved body composition, metabolic health, and potentially reduced cardiovascular risk.

Tesamorelin is administered as a subcutaneous injection, typically into the abdominal area.

HIV-associated lipodystrophy is a condition characterized by changes in body fat distribution, often seen in individuals with HIV undergoing antiretroviral therapy.

Tesamorelin stimulates the pituitary gland to release more growth hormone, which can lead to a reduction in visceral adipose tissue.

Individuals with HIV-associated lipodystrophy and excess abdominal fat may be candidates for Tesamorelin therapy. Consult a healthcare professional for proper evaluation.

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog used to reduce excess abdominal fat in individuals with HIV-associated lipodystrophy.

Peptides are short-chain amino acids, which are naturally present in foods and easily absorbed due to their small size. Different peptides target specific functions based on your goals. Our team can recommend the best peptides for you.